# Kevin Sayer

Episod podcast teratas
Dikemas kini:

In the News.. Dexcom 15-day sensor update, TrialNet milestone, Beta Bionic IPO, and more!

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Dexcom updates investors on its 15-day sensor, TrialNet marks a big anniversary, Beta Bionics goes public, NFL fans support Mark Andrews and much more! Find out more about Moms' Night ...

Ep 14 - Stryker's Kevin Lobo, Dexcom's Kevin Sayer talk diversity, COVID-19; also more on Medtronic deal

This week’s DeviceTalks Weekly podcast episode talks with industry leaders about improving worker diversity and developing new ways to treat COVID-19 patients. Kevin Lobo, chairman and CEO of Stryker, explains how his company – and the industry group AdvaMed – has been working  to increase dive ...

Updates from Dexcom at ADA 2025, with Kevin Sayer

In this special episode recorded at 85th Scientific Sessions of the American Diabetes Association (ADA 2025), hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Clevel ...

Building a $33B Digital Health Juggernaut | Dexcom Chairman & CEO Kevin Sayer

Dexcom generates more than $4 billion in annual revenue and has a market cap north of $30 billion, making it one of the biggest digital health companies in the world. And it all started with a better way to measure blood sugar. In this episode, Halle is joined by Kevin Sayer, CEO of Dexcom, the ...

In the News.. A new insulin approved, DOJ rules on CGM in schools, T2D artificial sweetener study, and more!

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: FDA approves the first fast-acting biosimilar insulin in the US, Tandem issues warning, DOJ stands up for remote monitoring in schools, GLP1 use protects against dementia, and more! F ...

Ep 90 - Diabetes Overview – Checking on promising tools from Dexcom, Bigfoot Biomedical and Senseonics

This week we’ll focus on a few of the exciting companies in the diabetes space. Associate Editor Sean Whooley first tracks down Dexcom CEO Kevin Sayer, who discusses the company’s next-generation G7 continuous glucose monitor, which is awaiting FDA approval. Then, Sean speaks with Bigfoot Bio ...

Ep 134 - Hear about Dexcom's evolving mission statement and Medtronic's Cranial and Spinal Technologies plans

In this week’s episode, CEO Kevin Sayer takes a few minutes to share Dexcom’s vision for the future OUTSIDE of diabetes. What does this mean for people with diabetes and others who could benefit from the powerful Dexcom G7? We also bring in a very popular interview from our MedtronicTalks podcas ...

In the News… $3 Semaglutide?, New Stem Cell Partnership, "Lyla's Law" Debate, Patient-Led Insulin Dosing in Pregnancy, FDA GLP-1 Crackdown, and more!

It's In the News, a look at the top headlines and stories in the diabetes community. This week's top stories: Stem Cell Islet Therapy Partnership, "Lyla's Law" Type 1 Testing Debate, Patient-Led Insulin Dosing for Gestational Diabetes, $3 Semaglutide Manufacturing, FDA GLP-1 Compounding Crackdo ...

How This Company Went From Nothing To $4 Billion!

Kevin Sayer spent 15 years as CEO of Dexcom, growing it from a niche startup into a $4 billion company that created the continuous glucose monitoring industry from scratch. In this episode of No Spotlight Needed, he sits down with Sheetal to tell the whole story: the early bets, the hard lessons ...

Pet Parents Keep Spending

Chewy’s growth depends on how much we love our furry friends. (00:21) Bill Barker and Deidre Woollard discuss: - The power of Chewy’s auto-ship service. - If Chewy’s growth is too dependent on macro trends. - What factors could lead to a Dollar General turnaround. (21:38) Mary Long talks with ...